| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 12.7 | 10.5 |
| Gross profit | 4.8 | 3.2 |
| Profit before tax | -3.5 | -4.2 |
| Net income | -3.5 | -4.3 |
| EPS (diluted, $ a share) | $-0.06 | $-0.08 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +21.5% |
|---|---|
| Gross margin | 38.0% |
| Operating margin | -25.2% |
10-Q filed with the SEC, NASDAQ: TKNO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Alpha Teknova, Inc.: key numbers
- Share price
- $7.77Close, Nov 16
- Market cap
- $489M
- Shares outstanding
- 62.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Alpha Teknova, Inc.
All →Alpha Teknova Financial Results
Alpha Teknova reported record third quarter 2026 revenue of $12.7 million, a 22% increase year-over-year, driven by strong demand in Clinical Solutions and Lab Essentials. Based on the performance, the company raised its full-year 2026 revenue guidance to a range of $46 million to $48 million.
- Term
- Q3 2026
“We posted record revenue for the second consecutive quarter. Growth was driven by increased sales of products to life science tools and diagnostics, and to biopharma customers. Notably, there was an increase in purchases of our custom products by small and mid-sized biotech customers and their associated contract manufacturers, which we believe is an early indication of biotech funding improvements over the past four quarters.”
Stephen Gunstream, President and Chief Executive Officer
“We delivered excellent financial results in the third quarter 2026 compared to 2025, highlighted by 22% revenue growth and a significant improvement in Adjusted EBITDA and Free Cash Outflow. We are therefore raising our 2026 revenue guidance to $46-48 million and maintaining our expectations for full-year Free Cash Outflow of less than $8 million.”
Matt Lowell, Chief Financial Officer
Alpha Teknova Capital Raise of $40M
Alpha Teknova, Inc. entered into an underwriting agreement for a public offering of 8,000,000 shares of common stock at $5.00 per share, generating $40 million in gross proceeds. The company granted underwriters a 30-day option to purchase up to 1,200,000 additional shares and intends to use the proceeds for general corporate purposes and potential debt repayment.
- Value
- $40M
- Counterparty
- TD Securities (USA) LLC